Pulling SEC filings + quote and writing the call…

Immuneering Corp
Next earnings ≈ Aug 14, 2026 · est. from filing cadence
Last earnings +0.4% on 2026-05-15
Conservative balance sheet (liabilities/equity 0.06x); but revenue fell -100.0% YoY.
Immuneering Corp shows $0.00 in FY2023 revenue (-100.0% YoY), and -25.6% ROE.
Sources: SEC EDGAR (CIK 0001790340, latest 10-Q filed 2026-05-15) · EODHD · as of 6/25/2026, 2:34:36 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.08M | $317K | $0.00 | — | — |
| Gross profit | $927K | $159K | $0.00 | — | — |
| Operating income | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| Net income | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| Diluted EPS | -$2.46 | -$1.91 | -$1.88 | -$2.04 | -$1.27 |
| Net margin | -1612.3% | -15937.3% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1075 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 2 open-market buys · 0 sales
| 2026-06-23 | Zeskind Benjamin J. PRESIDENT AND CEO | Buy | 2.40K @ $4.56 | $10.9K |
| 2026-06-15 | Hall Brett Matthew CHIEF SCIENTIFIC OFFICER | Buy | 6.04K @ $4.15 | $25.0K |
| 2026-03-13 | Neufeld Leah R CHIEF PEOPLE OFFICER | Award | 3.63K @ $4.29 | $15.6K |